Chugai Pharmabody
Chugai Pharmabody Research (CPR) is dedicated to innovative antibody research and drug discovery, collaborating with academia, industry, and government to develop therapeutics that address unmet medical needs. The company actively participates in scientific symposia, supports education, and celebrates milestones such as anniversaries and scientific events, emphasizing continuous improvement and fostering scientific progress. CPR also engages in outreach activities such as science education programs, industry collaborations, and community events to promote science and technology.
Industries
Nr. of Employees
medium (51-250)
Chugai Pharmabody
1 Fusionopolis Way, #07-01, Singapore 138632
Patents
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-12187786-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
US-11780908-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-10844113-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-10604561-B2
View Details
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-12187786-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
US-11780908-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-10844113-B2
View DetailsAnti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US-10604561-B2
View DetailsProducts
T‑cell engaging bispecific antibody platform
A bispecific antibody platform designed to engage T cells and improve tumor cell killing in preclinical models, suitable for lead optimization in immuno‑oncology programs.
Tumor‑selective agonist antibody modality
An antibody modality engineered to exert agonist activity selectively within tumor microenvironments activated by pathological signals to limit systemic on‑target toxicity.
Early‑stage antibody production and screening platform
A platform addressing early discovery antibody production bottlenecks to increase throughput for screening and reagent supply.
T‑cell engaging bispecific antibody platform
A bispecific antibody platform designed to engage T cells and improve tumor cell killing in preclinical models, suitable for lead optimization in immuno‑oncology programs.
Tumor‑selective agonist antibody modality
An antibody modality engineered to exert agonist activity selectively within tumor microenvironments activated by pathological signals to limit systemic on‑target toxicity.
Early‑stage antibody production and screening platform
A platform addressing early discovery antibody production bottlenecks to increase throughput for screening and reagent supply.
Services
Design and engineering of antibody formats (including recycling/sweeping mechanisms and bispecific constructs) to support discovery and lead generation.
Protein engineering, in vitro characterization, and in vivo efficacy testing to advance preclinical candidates toward clinical entry.
Expression and purification workflows for antibodies and other therapeutic proteins to supply discovery, screening, and structural studies.
Implementation of automated laboratory workflows and centralized data pipelines to improve throughput and reproducibility in discovery projects.
Partnerships with academic institutes and research agencies, including symposia, guest lectures, lab tours and educator engagement to facilitate translational research and science education.
Design and engineering of antibody formats (including recycling/sweeping mechanisms and bispecific constructs) to support discovery and lead generation.
Protein engineering, in vitro characterization, and in vivo efficacy testing to advance preclinical candidates toward clinical entry.
Expression and purification workflows for antibodies and other therapeutic proteins to supply discovery, screening, and structural studies.
Implementation of automated laboratory workflows and centralized data pipelines to improve throughput and reproducibility in discovery projects.
Partnerships with academic institutes and research agencies, including symposia, guest lectures, lab tours and educator engagement to facilitate translational research and science education.
Expertise Areas
- Antibody engineering
- Bispecific antibody development
- Tumor microenvironment‑activated modalities
- Recombinant protein production
Key Technologies
- Antibody engineering
- Bispecific antibody platforms
- T‑cell engaging bispecific formats
- Tumor microenvironment‑activated design
News & Updates
A symposium co-organised by CPR and A*STAR, showcasing cutting-edge antibody research.
Held on 23 September 2019, with around 300 participants, focusing on antibody therapeutics and diagnostics.
Held in 2013, with 11 scientists presenting updates in antibody research.
Held in 2015, focusing on antibody therapeutics and diagnostics.
Held in 2016, with around 300 attendees, featuring keynote speakers from Stanford and Osaka University.
Held in 2018, jointly organized with Denka Life Innovation Research and NTU.
A symposium co-organised by CPR and A*STAR, showcasing cutting-edge antibody research.
Held on 23 September 2019, with around 300 participants, focusing on antibody therapeutics and diagnostics.
Held in 2013, with 11 scientists presenting updates in antibody research.
Held in 2015, focusing on antibody therapeutics and diagnostics.
Held in 2016, with around 300 attendees, featuring keynote speakers from Stanford and Osaka University.
Held in 2018, jointly organized with Denka Life Innovation Research and NTU.